FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994936719> ?p ?o ?g. }

• W1994936719 endingPage "A411" @default.
• W1994936719 startingPage "A411" @default.
• W1994936719 abstract "Qutenza® is a novel method of action for the treatment of patients with peripheral neuropathic pain. Therefore it is important to assess the economic impact of introducing Qutenza® in the Spanish market for the treatment of neuropathic pain in adult patients. A budget impact model was developed using published data on disease prevalence and treatment, population growth, drug tariffs, health care resource utilization, unit costs and market shares forecasts for Spain. The perspective of the Spanish national health care system was chosen, using a 5-year time horizon. Treatments analyzed in this study were carbamazepine, capsaicin cream, pregabalin, lidocaine, duloxetine, amitriptyline, gabapentin and Qutenza®. Costs considered included drug costs, physician visits, diagnostic tests, hospitalisation and complementary non-pharmacological treatment. All costs referred to EUR 2010. Direct medical annual costs per patient for each treatment were estimated before and after the introduction of Qutenza® in order to estimate the total annual healthcare costs. Based upon the Spanish adult population data, the diagnosed population for 2010 suffering from neuropathic pain was estimated at 235,480 adult patients of whom 217,819 were assumed to receive treatment for their disease. Increases in the diagnosed and treated population were expected with estimates of 236,224 and 218,507 patients in 2015, respectively. Total health care costs over the next 5 years were estimated at €2695 million. Qutenza® was estimated to grow from 1.6% in the first year up to 5.6% in the fifth year. Under these conditions, total healthcare costs were estimated at €2,679 million. Mean annual costs per patient before the introduction of Qutenza® were estimated at €2,059 and at €2,046 after its introduction. The introduction of Qutenza® is likely to decrease the budget impact of neuropathic pain treatments for the Spanish national health care system. Overall savings in the economic burden of €16.7 million were found over the next 5 years." @default.
• W1994936719 created "2016-06-24" @default.
• W1994936719 creator A5015775538 @default.
• W1994936719 creator A5046467060 @default.
• W1994936719 creator A5054608675 @default.
• W1994936719 date "2011-11-01" @default.
• W1994936719 modified "2023-10-06" @default.
• W1994936719 title "PSY8 Neuropathic Pain: a Budget Impact Analysis to Estimate Costs Due to the Introduction of Qutenza® on the Spanish Market" @default.
• W1994936719 doi "https://doi.org/10.1016/j.jval.2011.08.981" @default.
• W1994936719 hasPublicationYear "2011" @default.
• W1994936719 type Work @default.
• W1994936719 sameAs 1994936719 @default.
• W1994936719 citedByCount "1" @default.
• W1994936719 countsByYear W19949367192014 @default.
• W1994936719 crossrefType "journal-article" @default.
• W1994936719 hasAuthorship W1994936719A5015775538 @default.
• W1994936719 hasAuthorship W1994936719A5046467060 @default.
• W1994936719 hasAuthorship W1994936719A5054608675 @default.
• W1994936719 hasBestOaLocation W19949367191 @default.
• W1994936719 hasConcept C118552586 @default.
• W1994936719 hasConcept C121955636 @default.
• W1994936719 hasConcept C142724271 @default.
• W1994936719 hasConcept C144133560 @default.
• W1994936719 hasConcept C160735492 @default.
• W1994936719 hasConcept C162324750 @default.
• W1994936719 hasConcept C182299520 @default.
• W1994936719 hasConcept C194828623 @default.
• W1994936719 hasConcept C204787440 @default.
• W1994936719 hasConcept C2776468701 @default.
• W1994936719 hasConcept C2776608144 @default.
• W1994936719 hasConcept C2777107010 @default.
• W1994936719 hasConcept C2780764818 @default.
• W1994936719 hasConcept C2908647359 @default.
• W1994936719 hasConcept C42219234 @default.
• W1994936719 hasConcept C50522688 @default.
• W1994936719 hasConcept C71924100 @default.
• W1994936719 hasConcept C99454951 @default.
• W1994936719 hasConceptScore W1994936719C118552586 @default.
• W1994936719 hasConceptScore W1994936719C121955636 @default.
• W1994936719 hasConceptScore W1994936719C142724271 @default.
• W1994936719 hasConceptScore W1994936719C144133560 @default.
• W1994936719 hasConceptScore W1994936719C160735492 @default.
• W1994936719 hasConceptScore W1994936719C162324750 @default.
• W1994936719 hasConceptScore W1994936719C182299520 @default.
• W1994936719 hasConceptScore W1994936719C194828623 @default.
• W1994936719 hasConceptScore W1994936719C204787440 @default.
• W1994936719 hasConceptScore W1994936719C2776468701 @default.
• W1994936719 hasConceptScore W1994936719C2776608144 @default.
• W1994936719 hasConceptScore W1994936719C2777107010 @default.
• W1994936719 hasConceptScore W1994936719C2780764818 @default.
• W1994936719 hasConceptScore W1994936719C2908647359 @default.
• W1994936719 hasConceptScore W1994936719C42219234 @default.
• W1994936719 hasConceptScore W1994936719C50522688 @default.
• W1994936719 hasConceptScore W1994936719C71924100 @default.
• W1994936719 hasConceptScore W1994936719C99454951 @default.
• W1994936719 hasIssue "7" @default.
• W1994936719 hasLocation W19949367191 @default.
• W1994936719 hasOpenAccess W1994936719 @default.
• W1994936719 hasPrimaryLocation W19949367191 @default.
• W1994936719 hasRelatedWork W2014185462 @default.
• W1994936719 hasRelatedWork W2080027527 @default.
• W1994936719 hasRelatedWork W2324402108 @default.
• W1994936719 hasRelatedWork W2428659504 @default.
• W1994936719 hasRelatedWork W2896769073 @default.
• W1994936719 hasRelatedWork W2964235968 @default.
• W1994936719 hasRelatedWork W2994632038 @default.
• W1994936719 hasRelatedWork W3185168217 @default.
• W1994936719 hasRelatedWork W4309261544 @default.
• W1994936719 hasRelatedWork W4321604098 @default.
• W1994936719 hasVolume "14" @default.
• W1994936719 isParatext "false" @default.
• W1994936719 isRetracted "false" @default.
• W1994936719 magId "1994936719" @default.
• W1994936719 workType "article" @default.